Allogene Therapeutics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALLO and other ETFs, options, and stocks.About ALLO
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.
ALLO Key Statistics
Stock Snapshot
With a market cap of 554.59M, Allogene Therapeutics(ALLO) trades at $2.18. The stock has a price-to-earnings ratio of -2.63.
As of 2026-04-15, Allogene Therapeutics(ALLO) stock has fluctuated between $2.17 and $3.08. The current price stands at $2.18, placing the stock +0.5% above today's low and -29.2% off the high.
The Allogene Therapeutics(ALLO)'s current trading volume is 42.32M, compared to an average daily volume of 16.72M.
In the last year, Allogene Therapeutics(ALLO) shares hit a 52-week high of $4.46 and a 52-week low of $0.86.
In the last year, Allogene Therapeutics(ALLO) shares hit a 52-week high of $4.46 and a 52-week low of $0.86.
ALLO News
Cellectis (CLLS) highlighted the interim futility analysis announced by Allogene Therapeutics (ALLO) from Allogene’s sponsored pivotal ALPHA3 trial evaluating c...
Allogene Therapeutics (ALLO) announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175M o...
Analyst ratings
87%
of 15 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.